Search

• GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

  Media

  Results from the ongoing AReSVi-006 phase III trial show vaccine efficacy over two full seasons

  https://www.gsk.com/en-gb/media/press-releases/gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/

  First published: 21 June 2023

• 

  GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+

  Media

  This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/

  First published: 02 February 2016

• GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older

  Media

  GSK announced the expanded indication for Fluarix Tetra has been approved in Europe.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-expanded-indication-for-fluarix-tetra-influenza-vaccine-for-ages-six-months-and-older/

  First published: 15 February 2018

• Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine

  Media

  GSK announced today that it has received a Complete Response letter from the FDA .

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-receives-complete-response-from-fda-for-candidate-pandemic-h5n1-adjuvanted-influenza-vaccine/

  First published: 25 March 2013

• Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval

  Media

  GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1).

  https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-european-commission-approval/

  First published: 30 September 2009

• Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines

  Media

  GSK announced results from five Phase III studies investigating two candidate quadrivalent influenza vaccines. presented in Spain & US.

  https://www.gsk.com/en-gb/media/press-releases/results-from-five-phase-iii-studies-presented-for-gsk-s-two-candidate-quadrivalent-influenza-vaccines/

  First published: 22 October 2012

• Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives positive opinion from European Regulators

  Media

  GSK announced EMA's CHMP has issued a positive opinion recommending approval of GSK's H1N1 adjuvanted vaccine Pandemrix.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-positive-opinion-from-european-regulators/

  First published: 24 September 2009

• GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China

  Media

  GSK announced it's entered into JV with Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-shenzhen-neptunus-create-new-alliance-to-develop-and-manufacture-influenza-vaccines-in-china/

  First published: 08 June 2009

• 

  ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

  Behind the science magazine

  Researchers are testing new ways to protect against infectious disease – and pursuing effective vaccines that have eluded them for decades.

  https://www.gsk.com/en-gb/behind-the-science-magazine/maps-technology-new-age-vaccine-development-infectious-diseases/

  First published: 09 January 2023

• Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results

  Media

  GSK today announced that, to date, more than 150,000 people have received GSK pandemic H1N1 vaccine, Pandemrix.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-experience-of-gsk-s-h1n1-adjuvanted-vaccine-pandemrix-and-preliminary-paediatric-results/

  First published: 23 October 2009